Published in Drug Dev Res on November 01, 2011
Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond B Biol Sci (2014) 1.29
Store-operated calcium entry: Mechanisms and modulation. Biochem Biophys Res Commun (2015) 0.97
Selective activation of KCa3.1 and CRAC channels by P2Y2 receptors promotes Ca(2+) signaling, store refilling and migration of rat microglial cells. PLoS One (2013) 0.94
Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts? ChemMedChem (2012) 0.86
Contribution of the KCa3.1 channel-calmodulin interactions to the regulation of the KCa3.1 gating process. J Gen Physiol (2013) 0.84
Kcnn4 is a regulator of macrophage multinucleation in bone homeostasis and inflammatory disease. Cell Rep (2014) 0.83
Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis (2014) 0.81
Molecular dynamics simulations of scorpion toxin recognition by the Ca(2+)-activated potassium channel KCa3.1. Biophys J (2013) 0.80
Immunosuppression by N-methyl-D-aspartate receptor antagonists is mediated through inhibition of Kv1.3 and KCa3.1 channels in T cells. Mol Cell Biol (2013) 0.80
KCa3.1/IK1 Channel Regulation by cGMP-Dependent Protein Kinase (PKG) via Reactive Oxygen Species and CaMKII in Microglia: An Immune Modulating Feedback System? Front Immunol (2015) 0.80
Impact of aging on calcium influx and potassium channel characteristics of T lymphocytes. Oncotarget (2015) 0.79
Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype. J Autoimmun (2016) 0.78
Targeting ion channels for the treatment of autoimmune neuroinflammation. Ther Adv Neurol Disord (2013) 0.78
NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. Cell Commun Signal (2014) 0.77
Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of Kv1.3 channels and T cell responsiveness. Oncotarget (2016) 0.75
Margatoxin-bound quantum dots as a novel inhibitor of the voltage-gated ion channel Kv1.3. J Neurochem (2016) 0.75
Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury. Exp Neurol (2016) 0.75
Kv1.3 channels facilitate the connection between metabolism and blood flow in the heart. Microcirculation (2017) 0.75
Effects of voltage-gated K+ channel on cell proliferation in multiple myeloma. ScientificWorldJournal (2014) 0.75
Differentially Expressed Potassium Channels Are Associated with Function of Human Effector Memory CD8(+) T Cells. Front Immunol (2017) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Rheumatoid arthritis. Lancet (2010) 9.37
Psoriasis. N Engl J Med (2009) 8.80
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature (1984) 4.70
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A (2000) 4.01
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res (2008) 3.76
Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med (2001) 3.75
The functional network of ion channels in T lymphocytes. Immunol Rev (2009) 3.21
Multiple sclerosis: a two-stage disease. Nat Immunol (2001) 3.20
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov (2009) 3.12
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol (2001) 3.00
K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature (1984) 2.89
Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem (2000) 2.85
Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res (2006) 2.67
Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A (2001) 2.63
hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc Natl Acad Sci U S A (1997) 2.31
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J Biol Chem (1997) 2.05
Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol (2008) 1.98
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J Biol Chem (1993) 1.94
Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J Gen Physiol (1993) 1.93
Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem (2007) 1.85
Expression and chromosomal localization of a lymphocyte K+ channel gene. Proc Natl Acad Sci U S A (1990) 1.85
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83
Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol (2004) 1.82
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4. J Biol Chem (2004) 1.81
CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood (2002) 1.81
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem (1999) 1.78
Kv1.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron (2004) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-6 in macrophages. Proc Natl Acad Sci U S A (2004) 1.65
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol (2004) 1.65
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol (2010) 1.56
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev Mol Diagn (2008) 1.53
Allergic contact dermatitis. Eur J Dermatol (2004) 1.52
K+ channels and the microglial respiratory burst. Am J Physiol Cell Physiol (2001) 1.51
Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol (2009) 1.46
Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc Natl Acad Sci U S A (1989) 1.44
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A (2009) 1.44
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Modulation of olfactory bulb neuron potassium current by tyrosine phosphorylation. J Neurosci (1998) 1.40
Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax (2006) 1.39
Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem (2010) 1.37
The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci (2007) 1.37
Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry (1999) 1.34
Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat Struct Biol (1996) 1.34
Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle. Proc Natl Acad Sci U S A (2002) 1.32
New pathophysiological insights and modern treatment of IBD. J Gastroenterol (2010) 1.31
Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J Biol Chem (2003) 1.31
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A (2010) 1.29
Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol (2009) 1.29
Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels. Mol Pharmacol (2003) 1.28
KCa3.1 Ca2+ activated K+ channels regulate human airway smooth muscle proliferation. Am J Respir Cell Mol Biol (2007) 1.20
Ca2(+)-activated K+ channels in human B lymphocytes and rat thymocytes. J Physiol (1989) 1.20
Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol (1999) 1.19
Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol Pharmacol (1996) 1.18
Chemical synthesis and characterization of maurotoxin, a short scorpion toxin with four disulfide bridges that acts on K+ channels. Eur J Biochem (1996) 1.17
Functional importance of Ca2+-activated K+ channels for lysophosphatidic acid-induced microglial migration. Eur J Neurosci (2004) 1.16
The K+ channel iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells. J Allergy Clin Immunol (2004) 1.15
A patch-clamp study of mammalian platelets and their voltage-gated potassium current. J Physiol (1987) 1.14
Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2003) 1.12
Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One (2008) 1.12
Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca(2+)-activated over voltage-gated K(+) channels. J Biol Chem (2000) 1.11
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J (2005) 1.11
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol (2005) 1.10
Resting and activation-dependent ion channels in human mast cells. J Immunol (2001) 1.10
Ras/MEK/ERK Up-regulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis. J Biol Chem (2000) 1.09
Blunted IgE-mediated activation of mast cells in mice lacking the Ca2+-activated K+ channel KCa3.1. J Immunol (2008) 1.09
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol (2009) 1.08
Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) (2007) 1.06
Binding of correolide to K(v)1 family potassium channels. Mapping the domains of high affinity interaction. J Biol Chem (1999) 1.05
Properties of K+ and Cl- channels and their involvement in proliferation of rat microglial cells. Glia (1996) 1.05
Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly. Pflugers Arch (2008) 1.04
Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel (2007) 1.03
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol (2010) 1.03
Clotrimazole in rheumatoid arthritis. Ann Rheum Dis (1980) 1.02
Basolateral K+ channels in airway epithelia. I. Regulation by Ca2+ and block by charybdotoxin. Am J Physiol (1990) 1.00
The fibroblast intermediate conductance K(Ca) channel, FIK, as a prototype for the cell growth regulatory function of the IK channel family. J Membr Biol (1999) 1.00
The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J Invest Dermatol (2010) 0.99
Differential regulation of voltage- and calcium-activated potassium channels in human B lymphocytes. J Immunol (1992) 0.96
Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma. Eur J Neurosci (2004) 0.96
KCNN4 gene variant is associated with ileal Crohn's Disease in the Australian and New Zealand population. Am J Gastroenterol (2010) 0.95
Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry (2002) 0.95
Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy (2006) 0.94
Ulcerative colitis and cancer. J Surg Oncol (2010) 0.93
Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem (2004) 0.93
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs (2009) 0.92
Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells. Am J Physiol (1993) 0.91
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev (2005) 2.39
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation (2009) 1.86
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int (2008) 1.80
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol (2008) 1.58
Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci (2011) 1.46
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A (2009) 1.44
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proc Natl Acad Sci U S A (2008) 1.38
Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem (2010) 1.37
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol (2004) 1.31
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A (2010) 1.29
Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets (2010) 1.29
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem (2003) 1.22
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J (2005) 1.11
The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab (2011) 1.08
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol (2009) 1.08
Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol (2012) 1.05
The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell (2009) 1.03
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet (2002) 1.01
The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochem J (2004) 0.98
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem (2001) 0.94
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One (2012) 0.94
AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology (2007) 0.94
The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem (2013) 0.93
Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem (2004) 0.93
Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Mol Pharmacol (2011) 0.92
Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr Med Chem (2004) 0.92
Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol (2010) 0.89
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem (2014) 0.89
Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One (2013) 0.89
Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. Int J Alzheimers Dis (2012) 0.89
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem (2006) 0.88
Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol (2012) 0.88
Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respir Res (2014) 0.86
Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol Pharmacol (2005) 0.86
Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new κ-KTX subfamily. Biochem Pharmacol (2012) 0.86
Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. Br J Pharmacol (2013) 0.85
SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts. Cardiovasc Res (2012) 0.85
Does microglial dysfunction play a role in autism and Rett syndrome? Neuron Glia Biol (2012) 0.84
K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLoS One (2013) 0.84
Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3. PLoS One (2013) 0.84
Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Mol Pharmacol (2014) 0.82
The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets (2013) 0.82
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem (2008) 0.81
The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLoS One (2013) 0.79
The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics (2015) 0.79
The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation (2013) 0.78
Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Drug Dev Ind Pharm (2010) 0.78
Channels: Sticking to nooks and crannies. Nat Chem Biol (2013) 0.77
Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay Drug Dev Technol (2013) 0.77
Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure. Pflugers Arch (2014) 0.77
Triarylmethanes, a new class of cx50 inhibitors. Front Pharmacol (2012) 0.76
Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. Pflugers Arch (2014) 0.76
Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels. J Cardiovasc Pharmacol (2015) 0.75
A simple device to illustrate the Einthoven triangle. Adv Physiol Educ (2012) 0.75
Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorg Med Chem Lett (2012) 0.75
Ion channels. Thorax (2013) 0.75
Development of tetramethylenedisulfotetramine (TETS) hapten library: synthesis, electrophysiological studies and immune response in rabbits. Chemistry (2017) 0.75